CING (Cingulate) רווח נקי למניה אחת בשנים עשר החודשים האחרונים

Cingulate Inc. is developing a line of ADHD treatments while awaiting FDA approval for a full market launch. The business relies on the CTR platform featuring a precision dosing system, which enhances physician loyalty. Diversification into anxiety treatment expands the patient reach. The TTM annual net income per share dynamics reflect a reaction to the cost of capital, where the 37.60 mark serves as the current indicator.

Clinical progress of the CTX-1301 drug for ADHD treatment and licensing prospects drive the investment attractiveness of Cingulate Inc. (CING). By analyzing the current YoY TTM net income per share growth, an investor evaluates the percentage change in earnings over the last four quarters relative to the same period last year, which reveals the actual efficiency of the business model and assesses the asset's resilience to market expectations.